Deerfield Management’s Melinta Therapeutics MLNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
– Sell
-356,952
Closed -$1.27M – 108
2019
Q1
$1.27M Buy
356,952
+290,172
+435% +$1.57M 0.05% 91
2018
Q4
$265K Sell
66,780
-395,592
-86% -$5.06M 0.01% 98
2018
Q3
$9.13M Sell
462,372
-336,789
-42% -$8.51M 0.33% 71
2018
Q2
$25.4M Buy
799,161
+173,592
+28% +$6.25M 0.89% 46
2018
Q1
$23.1M Buy
+625,569
New +$41.1M 0.8% 50

Other funds holding MLNT

Deerfield Management's MLNT Position: Q2 2019 in Review

Deerfield Management sold out of Melinta Therapeutics (MLNT) in Q2 2019, closing a stake of 356,952 shares — an estimated $1.27M sold.

Deerfield Management first reported a position in MLNT in Q1 2018 and held it in 5 quarters. The position peaked at $25.4M in Q2 2018. 53 funds tracked by Wall St. Rank hold MLNT as of Q2 2019.

  • Deerfield Management reported no remaining Melinta Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Deerfield Management sold 356,952 Melinta Therapeutics shares in Q2 2019, an estimated $1.27M.
  • Deerfield Management first reported a position in Melinta Therapeutics in Q1 2018 and held it in 5 quarters.
  • Deerfield Management's Melinta Therapeutics position peaked at $25.4M in Q2 2018.
  • 53 funds tracked by Wall St. Rank held Melinta Therapeutics as of Q2 2019.

Based on Deerfield Management's 13F filing for Q2 2019, filed 14 Aug 2019.